Similar Search Results

Insensitivity to Scope in Contingent Valuation Studies: Reason for Dismissal of Valuations?

Søgaard, Rikke Sgaard; Lindholt, Jes; Gyrd-Hansen, Dorte - In: Applied Health Economics and Health Policy 10 (2012) 6, pp. 397-405

Background:Background: The credibility of contingent valuation studies has been questioned because of the potential occurrence of scope insensitivity, i.e. that respondents do not react to higher quantities or qualities of a good. Abstract: Objective:Objective: The aim of this study was to...

Persistent link: https://www.econbiz.de/10011005065

Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain: The ECOBIM Study

Dilla, Tatiana; Valladares, Amparo; Nicolay, Claudia; … - In: Applied Health Economics and Health Policy 10 (2012) 6, pp. 417-430

, little is known about the impact of weight loss or body mass index (BMI) reduction on type 2 diabetes-related healthcare … costs. Abstract: Objective:Objective: The aim of this study was to estimate the economic impact of change in BMI among …

Persistent link: https://www.econbiz.de/10011005066

What Explains Willingness to Pay for Smoking-Cessation Treatments - Addiction Level, Quit-Rate Effectiveness or the Opening Bid?

Olsen, Jan Abel.; Røgeberg, Ole J. Rgeberg; Stavem, Knut - In: Applied Health Economics and Health Policy 10 (2012) 6, pp. 407-415

was, in addition, asked about their WTP for a hypothetical treatment that would remove their urge to smoke. The impact of …

Persistent link: https://www.econbiz.de/10011005067

Do Productivity Costs Matter?: The Impact of Including Productivity Costs on the Incremental Costs of Interventions Targeted at Depressive Disorders

Krol, Marieke; Papenburg, Joc; Koopmanschap, Marc; … - In: PharmacoEconomics 29 (2011) 7, pp. 601-619

analyse the impact of productivity costs on final results. Regression analyses were used to investigate the relationship …

Persistent link: https://www.econbiz.de/10011005068

Is There a Role for Pharmacoeconomics in Developing Countries?

Harper, Jonathan R. - In: PharmacoEconomics 29 (2011) 5, pp. 435-436

Persistent link: https://www.econbiz.de/10011005069

Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer: A Systematic Review

Bongers, Mathilda L.; Coupé, Veerle M.H. Coup; Jansma, … - In: PharmacoEconomics 30 (2012) 1, pp. 17-34

In past decades, studies focusing on new chemotherapeutic agents for patients with inoperable non-small-cell lung cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic evidence is lacking on superiority of one agent in terms of...

Persistent link: https://www.econbiz.de/10011005070

Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre

Heimeshoff, Mareike; Hollmeyer, Helge; Schreyogg, Jonas … - In: PharmacoEconomics 30 (2012) 9, pp. 763-777

Background:Background: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among Whites worldwide. Because many of these patients experience chronic endobronchial colonization and have to take antibiotics and be treated as inpatients, societal costs of CF may be high. As the...

Persistent link: https://www.econbiz.de/10011005071

Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets

Augestad, Liv Ariane; Rand-Hendriksen, Kim; … - In: PharmacoEconomics 30 (2012) 12, pp. 1203-1214

between pairs of EQ-5D health states within each value set and used the difference in transition scores as a measure of impact … dataset reduced this absolute difference to 0.02. The choice of regression model had little overall impact on the differences … study populations as reflected in the datasets. Changing the regression model had little impact on the differences between …

Persistent link: https://www.econbiz.de/10011005072

Impact of Treatment Success on Health Service Use and Cost in Depression: Longitudinal Database Analysis

Byford, Sarah; Barrett, Barbara; Despiégel, Nicolas … - In: PharmacoEconomics 29 (2011) 2, pp. 157-170

otherwise, of depression management strategies, and the economic impact over the longer term. Objective: To investigate the … economic impact of non-remission on health service use and costs over 12 months from the index episode in patients with …

Persistent link: https://www.econbiz.de/10011005073

Cost Effectiveness of Denosumab Compared with Oral Bisphosphonates in the Treatment of Post-Menopausal Osteoporotic Women in Belgium

Hiligsmann, Mickal; Reginster, Jean-Yves - In: PharmacoEconomics 29 (2011) 10, pp. 895-911

Background: Denosumab has recently been shown to be well tolerated, to increase bone mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial. It is...

Persistent link: https://www.econbiz.de/10011005074